source
- Roche reports positive interim Phase 3 results for kidney drug, paving way for accelerated approvalRoche announced interim results from its Phase 3 trial of a kidney disease therapy, indicating the study met its primary endpoints. The data, released on Wednesday, suggest the drug could qualify…
- FDA shift sparks renewed pharma and VC focus on osteoporosis drug developmentThe FDA recently altered its regulatory framework for osteoporosis medicines, prompting a wave of renewed interest across the pharmaceutical sector. Earlier, drugs from Eli Lilly, Merck, Novartis…